TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$120 Million

Loxo Oncology

Follow-on Offering

Bookrunner, January 2017

Loxo Oncology is a biopharmaceutical company focused on the innovation and development of highly selective medicines for patients with genetically defined cancers. The company’s pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Loxo’s management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible.